Neurosigma has signed a contract with the University of California, Los Angeles to fund a paediatric trial to investigate a non-invasive, external trigeminal nerve stimulation as a treatment for attention deficit hyperactivity disorder (ADHD).
The open-label Phase I clinical study will involve ten children with the disorder.
Previous clinical studies have shown that external trigeminal nerve stimulation is well tolerated, and that the low-energy stimulus is confined to the soft tissues of the forehead and does not penetrate into the brain.
NeuroSigma president and CEO Leon Ekchian said that the company’s non-invasive external trigeminal nerve stimulation therapy may help to treat ADHD without causing side effects.
The company expects to initiate the trial next month.